Russell Investments Group Ltd. Buys 11,878 Shares of Bruker Corporation $BRKR

Russell Investments Group Ltd. grew its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 154.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,558 shares of the medical research company’s stock after acquiring an additional 11,878 shares during the quarter. Russell Investments Group Ltd.’s holdings in Bruker were worth $816,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the business. CGN Advisors LLC increased its holdings in Bruker by 1.4% in the 1st quarter. CGN Advisors LLC now owns 22,014 shares of the medical research company’s stock worth $919,000 after buying an additional 296 shares in the last quarter. New York State Teachers Retirement System increased its holdings in Bruker by 0.8% in the 1st quarter. New York State Teachers Retirement System now owns 37,115 shares of the medical research company’s stock worth $1,549,000 after buying an additional 300 shares in the last quarter. State of Michigan Retirement System increased its holdings in Bruker by 1.1% in the 1st quarter. State of Michigan Retirement System now owns 26,493 shares of the medical research company’s stock worth $1,106,000 after buying an additional 300 shares in the last quarter. Louisiana State Employees Retirement System increased its holdings in Bruker by 1.0% in the 1st quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the medical research company’s stock worth $1,294,000 after buying an additional 300 shares in the last quarter. Finally, KBC Group NV increased its holdings in Bruker by 0.8% in the 1st quarter. KBC Group NV now owns 44,715 shares of the medical research company’s stock worth $1,866,000 after buying an additional 349 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Bruker

In related news, CEO Frank H. Laukien acquired 2,608 shares of the stock in a transaction dated Friday, June 6th. The shares were purchased at an average cost of $38.36 per share, with a total value of $100,042.88. Following the transaction, the chief executive officer directly owned 38,462,171 shares in the company, valued at approximately $1,475,408,879.56. This represents a 0.01% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 27.30% of the stock is currently owned by insiders.

Bruker Stock Up 1.6%

BRKR stock opened at $33.98 on Friday. Bruker Corporation has a twelve month low of $30.00 and a twelve month high of $72.94. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31. The stock has a market cap of $5.16 billion, a P/E ratio of 65.35, a PEG ratio of 2.75 and a beta of 1.16. The business’s 50-day moving average price is $38.04 and its 200-day moving average price is $40.35.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company had revenue of $797.40 million for the quarter, compared to analysts’ expectations of $811.17 million. During the same period in the previous year, the firm earned $0.52 earnings per share. The firm’s quarterly revenue was down .4% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, equities research analysts forecast that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 3rd. Stockholders of record on Tuesday, September 23rd will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Tuesday, September 23rd. Bruker’s payout ratio is presently 38.46%.

Analysts Set New Price Targets

Several research firms recently commented on BRKR. Bank of America reduced their price objective on Bruker from $61.00 to $50.00 and set a “buy” rating for the company in a report on Thursday, June 26th. Stifel Nicolaus set a $40.00 price objective on Bruker and gave the stock a “hold” rating in a report on Tuesday, August 5th. The Goldman Sachs Group dropped their target price on Bruker from $50.00 to $45.00 and set a “neutral” rating on the stock in a research report on Thursday, May 8th. Citigroup dropped their target price on Bruker from $40.00 to $38.00 and set a “neutral” rating on the stock in a research report on Monday, August 4th. Finally, Wells Fargo & Company dropped their target price on Bruker from $60.00 to $50.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 5th. Five research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $51.30.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.